Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI   US72940R1023

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/16/2015 01/20/2015 01/21/2015 01/22/2015 01/23/2015 Date
2.79(c) 2.82(c) 2.73(c) 2.7(c) 2.68(c) Last
111 892 80 142 66 787 85 039 37 903 Volume
+3.72% +1.08% -3.19% -1.10% -0.74% Change
More quotes
Company
Pluristem Therapeutics, Inc. is a bio-therapeutic company, which develops standardized cell therapy products for the treatment of life threatening diseases.The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a... 
Sector
Biotechnology & Medical Research
Calendar
01/27 | 03:30pmPresentation
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 0,38 M
EBIT 2015 -30,2 M
Net income 2015 -36,7 M
Debt 2015 -
Yield 2015 -
Sales 2016 10,3 M
EBIT 2016 -29,7 M
Net income 2016 -33,1 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 498x
Capi. / Sales 2016 18,3x
Capitalization 188 M
More Financials
Latest news on PLURISTEM THERAPEUTICS INC
01/13 Pluristem to Present at Two Cell Therapy Conferences in January 2015
01/12 PLURISTEM THERAPEUTICS : Regulation FD Disclosure, Financial Statements and Exhi..
01/12 Pluristem Issues Letter to Shareholders
01/09 PLURISTEM THERAPEUTICS : Granted Patent for Foundational Cell Harvesting Technol..
01/06 PLURISTEM THERAPEUTICS : New Published Paper Shows Placental Cells Protect Neuro..
2014 PLURISTEM THERAPEUTICS : New Published Data Show Pluristem’s PLX Cells Pro..
2014 PLURISTEM THERAPEUTICS INC. : When Considering Cell Therapy Investments - Not Al..
2014 PLURISTEM THERAPEUTICS : and Hadassah Medical Center Will Collaborate to Study P..
More news
Sector news Biotechnology & Medical Research - NEC
01/23 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
01/23 MEDIVATION : Astellas -enzalutamide phase 2 terrain trial demonstrated statistic..
01/22 QUINTILES TRANSNATIONAL : Investigator Initiated Trials is Topic of New Handbook..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF